RS58328B1 - Supstituisani 2,4 diamino-hinolini kao novi antitumorski agensi - Google Patents

Supstituisani 2,4 diamino-hinolini kao novi antitumorski agensi

Info

Publication number
RS58328B1
RS58328B1 RS20190110A RSP20190110A RS58328B1 RS 58328 B1 RS58328 B1 RS 58328B1 RS 20190110 A RS20190110 A RS 20190110A RS P20190110 A RSP20190110 A RS P20190110A RS 58328 B1 RS58328 B1 RS 58328B1
Authority
RS
Serbia
Prior art keywords
diamino
quinoline
substituted
anticancer agents
new anticancer
Prior art date
Application number
RS20190110A
Other languages
English (en)
Inventor
Firas Bassissi
Antoine Beret
Sonia Brun
Jérôme Courcambeck
Clarisse Dubray
Gregory Nicolas
Philippe Halfon
Original Assignee
Genoscience Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genoscience Pharma Sas filed Critical Genoscience Pharma Sas
Publication of RS58328B1 publication Critical patent/RS58328B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
RS20190110A 2014-10-31 2015-10-26 Supstituisani 2,4 diamino-hinolini kao novi antitumorski agensi RS58328B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462073325P 2014-10-31 2014-10-31
EP15837091.6A EP3212629B1 (en) 2014-10-31 2015-10-26 Substituted 2,4 diamino-quinoline as new anticancer agents
PCT/IB2015/002438 WO2016067112A1 (en) 2014-10-31 2015-10-26 Substituted 2,4 diamino-quinoline as new anticancer agents

Publications (1)

Publication Number Publication Date
RS58328B1 true RS58328B1 (sr) 2019-03-29

Family

ID=55404745

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20190110A RS58328B1 (sr) 2014-10-31 2015-10-26 Supstituisani 2,4 diamino-hinolini kao novi antitumorski agensi

Country Status (34)

Country Link
US (1) US10722505B2 (sr)
EP (1) EP3212629B1 (sr)
JP (1) JP6588546B2 (sr)
KR (1) KR102548547B1 (sr)
CN (1) CN107148416B (sr)
AU (1) AU2015338844B2 (sr)
CA (1) CA2965262C (sr)
CL (1) CL2017001073A1 (sr)
CO (1) CO2017007325A2 (sr)
CR (1) CR20170177A (sr)
CY (1) CY1121326T1 (sr)
DK (1) DK3212629T3 (sr)
DO (1) DOP2017000107A (sr)
EA (1) EA037119B1 (sr)
EC (1) ECSP17026748A (sr)
ES (1) ES2707125T3 (sr)
GE (1) GEP20207108B (sr)
HR (1) HRP20190107T1 (sr)
IL (1) IL251775B (sr)
LT (1) LT3212629T (sr)
MA (1) MA40875B1 (sr)
MY (1) MY193740A (sr)
NI (1) NI201700052A (sr)
PE (1) PE20191142A1 (sr)
PH (1) PH12017500810A1 (sr)
PL (1) PL3212629T3 (sr)
PT (1) PT3212629T (sr)
RS (1) RS58328B1 (sr)
SG (1) SG11201703479SA (sr)
SI (1) SI3212629T1 (sr)
TN (1) TN2017000168A1 (sr)
TR (1) TR201900148T4 (sr)
UA (1) UA122062C2 (sr)
WO (1) WO2016067112A1 (sr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6969800B2 (ja) * 2016-05-04 2021-11-24 ジェノシアンス ファルマ 増殖性疾患の治療に使用される置換2,4−ジアミノ−キノリン誘導体
US11065265B2 (en) 2018-05-18 2021-07-20 Spes Pharmaceuticals Inc. Compositions of fosaprepitant and methods of preparation
EP3620164A1 (en) 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2022033459A1 (zh) * 2020-08-10 2022-02-17 萧乃文 双非癌药物用于制备治疗癌症的医药组合物的用途
CN112375081B (zh) * 2020-11-23 2022-04-12 中国医学科学院医药生物技术研究所 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
CN112876673B (zh) * 2021-01-25 2021-12-24 山东大学 一种pH响应性纳米共聚物载体及其制备方法和应用
EP4349336A1 (en) 2022-10-04 2024-04-10 Genoscience Pharma Combination of substituted 2,4 diamino-quinoline compounds and mek inhibitors for use in the treatment of liver cancers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8580301A1 (es) * 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
US7759336B2 (en) 2002-12-10 2010-07-20 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
EP1601357A4 (en) * 2003-03-10 2007-10-03 Schering Corp HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS
SG10201705662WA (en) * 2013-01-15 2017-08-30 Incyte Corp Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
BR112015023948A2 (pt) * 2013-03-18 2017-07-18 Genoscience Pharma composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer

Also Published As

Publication number Publication date
CA2965262A1 (en) 2016-05-06
DK3212629T3 (en) 2019-02-18
ECSP17026748A (es) 2018-03-31
TN2017000168A1 (en) 2018-10-19
ES2707125T3 (es) 2019-04-02
NI201700052A (es) 2017-09-11
CA2965262C (en) 2023-03-14
LT3212629T (lt) 2019-01-10
CN107148416B (zh) 2020-05-05
PL3212629T3 (pl) 2019-05-31
US10722505B2 (en) 2020-07-28
EP3212629A1 (en) 2017-09-06
MY193740A (en) 2022-10-27
EA201790949A1 (ru) 2018-02-28
EA037119B1 (ru) 2021-02-09
CR20170177A (es) 2017-09-19
SG11201703479SA (en) 2017-05-30
BR112017018637A2 (pt) 2022-07-05
PH12017500810A1 (en) 2017-10-02
PE20191142A1 (es) 2019-09-02
MA40875A (fr) 2017-09-06
GEP20207108B (en) 2020-05-11
AU2015338844B2 (en) 2019-09-19
KR102548547B1 (ko) 2023-06-27
TR201900148T4 (tr) 2019-02-21
UA122062C2 (uk) 2020-09-10
AU2015338844A1 (en) 2017-05-04
CL2017001073A1 (es) 2018-01-12
PT3212629T (pt) 2019-02-04
CN107148416A (zh) 2017-09-08
WO2016067112A1 (en) 2016-05-06
EP3212629B1 (en) 2018-10-24
CO2017007325A2 (es) 2017-10-20
DOP2017000107A (es) 2017-09-15
IL251775B (en) 2020-07-30
SI3212629T1 (sl) 2019-02-28
NZ731345A (en) 2023-09-29
JP2017538673A (ja) 2017-12-28
GEAP202014494A (en) 2020-01-27
MA40875B1 (fr) 2019-01-31
KR20170077160A (ko) 2017-07-05
JP6588546B2 (ja) 2019-10-09
US20190314359A1 (en) 2019-10-17
IL251775A0 (en) 2017-06-29
HRP20190107T1 (hr) 2019-03-08
CY1121326T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
IL288232A (en) 1,7- naphthyridine as immunomodulators
IL282167A (en) Metabolized carbonucleosides and their use for cancer treatment
ZA201605622B (en) 1,3-benzodioxole derivative
HRP20190107T1 (hr) Supstituirani 2,4 diamino-kinolin kao novi antikancerogeni agens
HUE051888T2 (hu) Rákellenes készítmények
IL251976A0 (en) Phage therapy
GB201418612D0 (en) Umajin 1
SG11201803584RA (en) 1,4-dicarbonyl-piperidyl derivatives
HK1254800A1 (zh) 2,3,4,5-四氫吡啶-6-胺衍生物
HK1253336A1 (zh) 吲哚並吡咯啉抗腫瘤藥物
HUE043314T2 (hu) 1,3-butadién szintézis
AU5625P (en) BG-3.324 Fragaria Xananassa
GB201519732D0 (en) Mrbr.2
GB201413121D0 (en) The E.M.S As Pripulsian
GB201418606D0 (en) Lifteye october 2014
GB201400595D0 (en) The E.M.S as propotsion
GB201420970D0 (en) eGURE, egure, Egure
GB201418846D0 (en) MicroSub 1
GB201416254D0 (en) LiftEye 2014
GB201414175D0 (en) Pris-map 1
GB201413386D0 (en) Taggstar 2
GB201413310D0 (en) Taggstar 2
GB201413313D0 (en) Kapiche 1
GB201412713D0 (en) Soundwall 2
GB201410173D0 (en) X-System 2.0